PD-L2產(chǎn)品信息
英文名稱：Programmed death-ligand 2
中文名稱：程序性死亡配體2
靶點別稱：PDL2,PD-L2,Butyrophilin B7-DC,CD273,PDCD1 ligand 2,PDCD1L2,PDCD1LG2
物種：Human / Mouse
屬性：Protein
標記：Biotin-labeled / Unconjugated
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
PD-L2分子背景
Programmed cell death 1 ligand 2 (PD-L2 or PDCD1 ligand 2) is also known as Butyrophilin B7-DC, CD antigen CD273, which belongs to the immunoglobulin superfamily or BTN/MOG family. The expression of PD-L2 is up-regulated by IFNG/IFN-gamma stimulation in monocytes and induced on dendritic cells grown from peripheral blood mononuclear cells with CSF2 and IL-4. PD-L2 Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. PD-L2 interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.
PD-L2用戶評價
關(guān)鍵字： PD-L2;PD-L2蛋白;PD-L2重組蛋白;程序性死亡配體2;PDL2;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。